Agenda & Faculty, July 11-14 2024
13:00
Registration Opens
13:50
Opening remarks – Ryan Fitzpatrick, CEO, MD Education
Session I
Moderators: Elias Jabbour, MD
14:00
CLL Highlights
William Wierda, MD MD Anderson Cancer Center, Houston, Texas
14:20
MDS Highlights
Rami Komrokji, MD Moffit Cancer Center, Florida
14:40
Panel Discussion
15:00
Coffee Break & Networking
15:20
Industry supported independent expert discussion
Session II
Moderators: Naval Daver, MD and Eunice Wang, MD
16:05
BPDCN Highlights
Naveen Pemmaraju, MD MD Anderson Cancer Center, Houston, Texas
16:25
Pediatric Leukemia Highlights
Branko Cuglievan, MD MD Anderson Cancer Center, Houston, Texas
16:45
CML Highlights
Hagop Kantarjian, MD MD Anderson Cancer Center, Houston, Texas
17:05
Panel Discussion
17:25
Adjourn
07:30am
Registration opens
Session III
Moderators: Charlie Craddock, MD and Courtney DiNardo, MD
08:10
Current and Future Research Directions in AML
Hagop Kantarjian MD MD Anderson Cancer Center, Houston, Texas
08:30
The Genetic landscape and molecular diagnostics in AML
Joseph D. Khoury, MD University of Nebraska, Nebraska
08:50
Optimizing frontline therapy for FLT3 mutated AML patients eligible for intensive
Harry P. Erba, MD Duke University, North Carolina
09:10
Genomic strategies to guide the choice of invasive treatment strategies in non-FLT3m AML
Amir Fathi, MD Massachusetts General Hospital, Massachusetts
09:30
Diagnostic and molecular work-up of newly diagnosed AML – The pathologists perspective
Sanam Loghavi, MD MD Anderson Cancer Center, Houston, Texas
09:50
Panel Discussion
10:10
Coffee Break & Networking
Session IV
Moderators: Ibrahim Aldoss, MD and Anjali Advani, MD
10:30
Molecular Biology
Charles Mullighan, MD St. Jude Children’s Research Hospital, Memphis, Tennessee
10:50
Philadelphia +ive ALL
Elias Jabbour, MD MD Anderson Cancer Center, Houston, Texas
11:10
Ph- ALL MRD –
Aaron Logan, MD UCSF Helen Diller Family Comprehensive Cancer Center, California
11:30
New Targets in ALL
Cristina Papayannidis, MD Austin Diagnostic Clinic, TX
11:50
Panel Discussion
12:10
Lunch Break & Group Photo
13:00
Industry supported independent expert discussion
Session V
Moderators: Naval Daver, MD and Eunice Wang, MD
13:45
Updates on the management and mechenisms of resistance in R/R FLT3m AML
Alexander Perl, MD Perelman School of Medicine, Pennsylvania
14:05
Emerging strategies to improve outcome of allo-transplant in AML
Charlie Craddock, MD Queen Elizabeth Hospital, Birmingham
14:25
How do I assess for MRD in clinical practice and how do I use MRD to guide post remission therapy
Farhad Ravandi, MD MD Anderson Cancer Center, Houston, Texas
14:45
How do I use IDH inhibitors in frontline and R/R setting: Single agent versus combinations
Courtney DiNardo, MD MD Anderson Cancer Center, Houston, Texas
15:05
Current status and future directions with menin inhibitors in AML
Eytan Stein, MD Memorial Sloan Kettering Cancer Center, New York City, New York.
15:25
Panel Discussion
15:45
Coffee Break & Networking
Session VI
Moderators: Bijal Shah, MD and Nitin Jain, MD
16:05
Integration of immune-therapy into frontline ALL – HCVAD experience
Elias Jabbour, MD MD Anderson Cancer Center, Houston, Texas
16:25
Integration of immune-therapy into frontline ALL – Regimens
Mark Litzow, MD Mayo Clinic, Florida
16:45
AYA ALL
Wendy Stock, MD The University of Chicago Medicine, Illinois
17:05
Transplant in ALL
Ibrahim Aldoss, MD City of Hope Comprehensive Cancer Center, California
17:25
Panel Discussion
17:45
Adjourn
08:00
Registration Opens
Session VII
Moderators: Tapan Kadia, MD and Eytan Stein, MD
Debate: Upfront triplets vs sequential therapies for the treatment of AML
09:00
The case for sequential therapies
Eunice Wang, MD Roswell Park Comprehensive Cancer Center, Buffalo, New York
09:10
The case for upfront triplets
Naval Daver, MD MD Anderson Cancer Center, Houston, Texas
09:20
Debate Discussion
09:30
Developing Immune and cellular therapies in AML
Yasmin Abaza, MD Northwestern University Feinberg School of Medicine, Illinois
09:50
Panel Discussion
10:10
Coffee Break & Networking
Session VIII
Moderators: Aaron Logan, MD and Jae Park, MD
10:30
Older ALL
Anjali Advani, MD Cleveland Clinic, Ohio
10:50
BC2 Inhibitors in AML
Daniel J. DeAngelo, MD Dana-Farber Cancer Institute, Massachusetts
11:10
PH – lite ALL
Marina Konopleva, MD Albert Einstein College of Medicine, New York
11:30
New drugs in T-Cell
Nitin Jain, MD MD Anderson Cancer Center, Houston, Texas
11:50
Panel Discussion
12:10
Lunch & Networking
13:00
Industry supported independent expert discussion
Session IX
Moderators: Dan Pollyea, MD and Farhad Ravandi, MD
13:45
Mechanisms of resistance and novel combinations with ventoclax based therapies in AML
Marina Konopleva, MD Albert Einstein College of Medicine, New York
14:05
Optimizing maintenance therapy in AML post-consolidation and post-transplant
Tapan Kadia, MD MD Anderson Cancer Center, Houston, Texas
14:25
Immune based and other novel approaches to move the bar forward in the treatment of MDS
Hetty Carraway, MD Cleveland Clinic, Ohio
14:45
Optimizing SCT approaches including conditioning the maintenance in AML
Elizabeth J Shpall, MD MD Anderson Cancer Center, Houston, Texas
15:05
Panel Discussion
15:25
Coffee Break & Networking
Session X
Moderators: Wendy Stock, MD and Marina Konopleva, MD
15:45
CAR-T: Finite therapy
Jae Park, MD Memorial Sloan Kettering Cancer Center, New York City, New York.
16:05
CAR-T: Bridging for ASCT
Bijal Shah, MD Moffitt Cancer Center, Florida
16:25
Future of ALL
Hagop Kantarjian, MD MD Anderson Cancer Center, Houston, Texas
